Coherus BioSciences   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Redwood City CA United States (2010)
Status: No NME R&D (2010)

Organization Overview

First Clinical Trial
2014
NCT02115750
First Marketed Drug
2018
filgrastim (neupogen)
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Coherus Biosciences, Inc. | COHERUS BIOSCIENCES INC | Coherus BioSciences (parent company for Zao InteKrin)

Active Ingredients

Marketed Drugs (3)

adalimumab (humira) (2021)

filgrastim (neupogen) (2018)

ranibizumab (lucentis) (2022)

Drugs in Phase 3 Trials (2)

adalimumab (humira) (1 trial)

etanercept (enbrel) (3 trials)

Drugs in Phase 2 Trials (2)

Key: Coherus BioSciences (0) Acquired (2)

pioglitazone (actos) (1 trial)

t131 (3 trials)

Drugs in Phase 1 Trials (1)

filgrastim (neupogen) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 3)

Arthritis, Rheumatoid (Phase 3)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Psoriasis (Phase 3)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 5